C-reactive protein in nipple aspirate fluid associated with gail model factors

Biological Research for Nursing

Volumn 9, Issue 2, 2007, Pages 108-116

  Lithgow, Diana ^a,d   Nyamathi, Adeline ^b   Elashoff, David ^b   Martinez Maza, Otoniel ^b   Covington, Chandice ^c  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NORTH DAKOTA   (United States)

^d NONE

Author keywords

Biomarkers; Breast cancer; C reactive protein; Gail model; Inflammatory proteins; Precancerous

Indexed keywords

C REACTIVE PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; BREAST TUMOR; CAUCASIAN; CROSS-SECTIONAL STUDY; FEMALE; HEALTH SURVEY; HUMAN; IMMUNOLOGY; KENYA; METABOLISM; MIDDLE AGED; NEGRO; NIPPLE; RISK FACTOR; UNITED STATES; WOMEN'S HEALTH;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH SURVEYS; HUMANS; KENYA; MICHIGAN; MIDDLE AGED; NIPPLES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; WOMEN'S HEALTH;

EID: 34548740170     PISSN: 10998004     EISSN: 15524175     Source Type: Journal    
DOI: 10.1177/1099800407306426     Document Type: Article

References (46)

1. Abbas, A., & Lichtman, A. (2001). Basic immunology: Functions and disorders of the immune system. Philadelphia, PA: W. B. Saunders.
2. American Cancer Society. (2005). Cancer facts and figures 2005. New York: Author.
3. Barth, P.J., Ebrahimade, S., Ramaswamy, A., & Moll, R. (2002). CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ and benign breast lesions. Virchows Archive, 440 (3). 298-303.
4. Black, S., Kushner, I., & Samols, D. (2004). C-reactive protein. Journal of Biological Chemistry, 279, 48487-48490.
5. Boehm, J.S., & Hahn, W.C. (2005). Understanding transformation: Progress and gaps. Current Opinion in Genetics and Development, 15, 13-17.
6. Bondy, M., Lustbader, E., Halabi, S., Ross, E., & Vogel, V. (1994). Validation of a breast cancer risk assessment model in women with a positive family history. Journal of the National Cancer Institute, 86, 620-625.
7. Calabro, P., Willerson, J.T., & Yeh, E.T.H. (2003). Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation, 108, 1930-1932.
8. Chauhan, H., Abraham, A., Phillips, J.R., Pringle, J.H., Walker, R.A., & Jones, J.L. (2003). There is more than one kind of myofibroblast: Analysis of CD34 expression in benign, in situ, and invasive breast lesions. Journal of Clinical Pathology, 56 (4). 271-276.
9. Costantino, J., Gail, M., Pee, D., Anderson, S., Redmond, C., & Benichou, J. (1999). Validation studies for models projecting the risk of invasive and total breast cancer incidence. Journal of the National Cancer Institute, 91, 1541-1548.
10. Covington, C., Mitchell-Gieleghem, A., Lawson, D., Ito, I., & Grubbs, C. (2001). Presence of carotenoid, an anti-carcinogenic marker, in nipple aspirates postlactation. In D. S. Newburg (Ed.), Bioactive components of human milk (pp. 143-152). New York: Kluwer Academic, Plenum Publishers.
11. Covington, C.Y., & Morton, K. (2003). Nipple fluid aspiration method and aspirator cup. (U.S. Patent No.: 6471660; 6517513).
12. Dooley, W.C., Ljung, B.M., Veronesi, U., Cazzaniga, M., Elledge, R.M., O'Shaughnessy, J.A., et al. (2001). Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. Journal of the National Cancer Institute, 93, 1624-1632.
13. Eskin, B.A. (1999). Fibrocystic disease of the breast. In B. A. Eskin, S. Asbellm, & L. Jardinem (Eds.), Breast disease for primary care physicians (pp. 65-73). New York: Parthenon.
14. Euhus, D.M., Leitch, A.M., Huth, J.F., & Peters, G.N. (2002). Limitations of the Gail model in the specialized breast cancer risk assessment clinic. Breast Journal, 8, 23.
15. Fentiman, I.S. (2001). Fixed and modifiable risk factors for breast cancer. Current Opinion in Oncology, 13, 420-425.
16. Gabay, C., & Kushner, I. (1999). Acute-phase proteins and other systemic responses to inflammation. New England Journal of Medicine, 340, 448-454.
17. Gail, M., Brinton, L., Byar, D., Corale, D.K., Green, S.B., Schairer, C., et al. (1989). Projecting individualized probabilities of developing breast cancer for White females who are being examined annually. Journal of the National Cancer Institute, 81, 1879-1886.
18. Gould, J.M., & Weiser, J.N. (2001). Expression of Creactive protein in the respiratory tract. Infection and Immunity, 69, 1747-1754.
19. Harding, C., Osundeko, O., Tetlow, L., Faragher, E.B., Howell, A., & Bundred, N.J. (2000). Hormonally regulated proteins in breast secretions have markers of target organ sensitivity. British Journal of Cancer, 82, 345-360.
20. Hsiung, R., Zhu, W.Z., Klein, G., Qin, N.Y., Rosenberg, A., Park, P., et al. (2002). High basic fibroblast growth factor levels in nipple aspirate fluid are correlated with breast cancer. Cancer Journal, 8, 303-310.
21. Institute of Medicine. (2000). Developing technologies for early detection of breast cancer. Washington, DC: IOM Committee for the Early Detection of Breast Cancer Workshop.
22. Jabs, W.J., Logering, B.A., Gerke, P., Kreft, B., Wolber, E.M., Klinger, M.H.F., et al. (2003). The kidney as a second site of human C-reactive protein formation in vivo. European Journal of Oncology, 33, 152-161.
23. Jabs, W.J., Theissing, E., Nitschke, M., Bechtel, J.F.M., Duchrow, M., & Mohamed, S. (2003). Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation, 108, 1428-1431.
24. Key, T.J., Verkasalo, P.K., & Banks, E. (2001). Epidemiology of breast cancer. Lancet, 358, 1389-1399.
25. Mallon, E., Osin, P., Nasiri, N., Blain, I., Howard, B., & Gusterson, B. (2000). The basic pathology of human breast cancer. Journal of Mammary Gland Biology, 5, 139-154.
26. Mortensen, R.F., & Rudczynski, A.B. (1982). Prognostic significance of serum CRP levels and lymphoid cell infiltrates in human breast cancer. Oncology, 39 (3). 129-133.
27. National Institutes of Health. (2005). National Cancer Institute: The Gail Model Breast Cancer Risk Assessment Tool. Accessed May 3, 2005, at http://bcra.nci.nih.gov/brc/q1.htm
28. Nielsen, H.J., Christensen, I.J., Sorensen, S., Moesgaard, F., & Brunner, N. (2000). Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. Annals of Surgical Oncology, 7, 617-623.
29. Robertson, J.F.R., Pearson, D., Price, M.R., Selby, C., Pearson, J., Blamey, R.W., et al. (1991). Prospective assessment of the role of 5 tumor markers in breast cancer. Cancer Immunology, Immunotherapy, 33, 403-410.
30. Rockhill, B., Spiegelman, D., Byrne, C., Hunter, D.J., & Colditz, G.A. (2001). Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. Journal of the National Cancer Institute, 93, 358-366.
31. Romagnolo, D., & DiAugustine, R.P. (1994). The mammary gland: Protein factory of the future. Environmental Health Perspectives, 102, 644-646.
32. Russo, J., Calaf, N., Sohi, N., Tahin, Q., Zhang, P.L., Alvarado, M.E., et al. (1993). Critical steps in breast carcinogenesis. Annals of the New York Academy of Sciences, 698, 1-20.
33. Salazar-Mather, T., & Hokeness, K. (2003). Calling in the troops: Regulation of inflammatory cell trafficking through innate cytokine/chemokine networks. Viral Immunology, 16, 291-306.
34. Sauter, E.R., Ehya, H., Schlatter, L., & Mac Gibbon, B. (2004). Ductoscopic cytology to detect breast cancer. Cancer Journal, 10 (1). 33-41.
35. Sauter, E.R., Ross, E., Day, M., Klein-Szanto, A., Engstrom, P.F., Sorling, A., et al. (1997). Nipple aspirate fluid: A promising non-invasive method to identify cellular markers of breast cancer risk. British Journal of Cancer, 76, 494-501.
36. Sauter, E.R., Shan, S., Hewett, J.E., Spookman, P., & Du Bois, G.C. (2005). Proteomic analysis of nipple aspirate fluid using SELDI-TOF-MS. International Journal of Cancer, 114, 791-796.
37. Sauter, E.R., Zhu, W., Fan, X.J., Wassell, R.P., Chervoneva, I., & Du Bois, C.G. (2002). Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. British Journal of Cancer, 86, 1440-1443.
38. Shao, Z., & Nguyen, M. (2001). Nipple aspiration in diagnosis of breast cancer. Seminars in Surgical Oncology, 20, 175-180.
39. Spiegelman, D., Colditz, G., Hunter, D., & Hertzmark, E. (1994). Validation of the Gail et al. model for predicting individual breast cancer risk. Journal of the National Cancer Institute, 86, 600-607.
40. Sukumar, S., & McKenzie, K. (1996). Breast cancer prevention strategies for the twenty-first century. Molecular Medicine Today, 2, 453-459.
41. Tice, J.A., Miike, R., Adduci, K., Petrakis, N.L., King, E., & Wrensch, M.R. (2005). Nipple aspirate fluid cytology and the Gail model for breast cancer risk assessment in a screening population. Cancer Epidemiology Biomarkers & Prevention, 14, 324-328.
42. Varnum, S.M., Covington, C.C., Woodbury, R.L., Petris, K., Kangas, L.J., Abdullah, M.S., et al. (2003). Proteomic characterization of nipple aspirate fluid: Identification of potential biomarkers of breast cancer. Breast Cancer Research and Treatment, 80 (1). 87-97.
43. Wei, W., Parvin, M.N., Tsumura, K., Akamatsu, T., Tada, J., Kanamori, N., et al. (2001). Induction of C-reactive protein, serum amyloid P component, and kininogens in the submandibular and lacrimal glands of rats with experimentally induced inflammation. Life Sciences, 69, 359-368.
44. Wrensch, M., Petrakis, N., Miike, R., King, E.B., Chew, K., Neuhaus, J., et al. (2001). Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. Journal of the National Cancer Institute, 93, 1791-1798.
45. Yasojima, K., Schwab, C., McGeer, E.G., & McGeer, P.L. (2001). Generation of C-reactive protein and complement components in atherosclerotic plaques. American Journal of Pathology, 158, 1039-1051.
46. Zangar, R., Varnum, S.M., Covington, C.Y., & Smith, R.D. (2004). A rational approach for discovering and validating cancer markers in very small samples using mass spectrometry and ELISA microarrays. Disease Markers, 20 (3). 135-148.